NO333586B1 - Krystallinsk clopidogrel og fremgangsmate for fremstilling derav - Google Patents

Krystallinsk clopidogrel og fremgangsmate for fremstilling derav Download PDF

Info

Publication number: NO333586B1
Authority: NO; Norway
Prior art keywords: clopidogrel; butyl; besylate; solvents; clopidogrel besylate
Prior art date: 2003-04-25

Application number

NO20054763A

Other languages

English (en)

Norwegian (no)

Other versions

NO20054763L (no

NO20054763D0 (no

Inventor

Braj Bhushan Lohray

Vidya Bhushan Lohray

Mayank Ghanshyambhai Dave

Original Assignee

Cadila Healthcare Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-25

Filing date

2005-10-17

Publication date

2013-07-15

2005-10-17 Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd

2005-10-17 Publication of NO20054763D0 publication Critical patent/NO20054763D0/no

2006-01-16 Publication of NO20054763L publication Critical patent/NO20054763L/no

2013-07-15 Publication of NO333586B1 publication Critical patent/NO333586B1/no

Links

GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 title claims abstract description 69
239000005552 B01AC04 - Clopidogrel Substances 0.000 title claims abstract description 32
229960003009 clopidogrel Drugs 0.000 title claims abstract description 31
238000000034 method Methods 0.000 title claims abstract description 20
238000002360 preparation method Methods 0.000 title abstract description 15
229950010557 clopidogrel besilate Drugs 0.000 claims abstract description 37
150000003839 salts Chemical class 0.000 claims abstract description 29
150000001875 compounds Chemical class 0.000 claims abstract description 7
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 42
239000002904 solvent Substances 0.000 claims description 27
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 23
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 14
239000000203 mixture Substances 0.000 claims description 13
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 9
229940092714 benzenesulfonic acid Drugs 0.000 claims description 9
238000004519 manufacturing process Methods 0.000 claims description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
125000000217 alkyl group Chemical group 0.000 claims description 6
150000002170 ethers Chemical class 0.000 claims description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 5
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
239000003208 petroleum Substances 0.000 claims description 5
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
238000004090 dissolution Methods 0.000 claims description 4
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
150000001298 alcohols Chemical class 0.000 claims description 2
238000000634 powder X-ray diffraction Methods 0.000 claims description 2
238000001757 thermogravimetry curve Methods 0.000 claims description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract description 3
239000003814 drug Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
238000002844 melting Methods 0.000 description 6
230000008018 melting Effects 0.000 description 6
239000011541 reaction mixture Substances 0.000 description 5
239000012453 solvate Substances 0.000 description 5
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
238000010992 reflux Methods 0.000 description 4
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
229940127218 antiplatelet drug Drugs 0.000 description 3
238000001914 filtration Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
FDEODCTUSIWGLK-RSAXXLAASA-N clopidogrel sulfate Chemical compound [H+].OS([O-])(=O)=O.C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl FDEODCTUSIWGLK-RSAXXLAASA-N 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
-1 t- butyl Chemical group 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical class CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
IKQCSJBQLWJEPU-UHFFFAOYSA-N 2,5-dihydroxybenzenesulfonic acid Chemical class OC1=CC=C(O)C(S(O)(=O)=O)=C1 IKQCSJBQLWJEPU-UHFFFAOYSA-N 0.000 description 1
MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 1
125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
239000004004 anti-anginal agent Substances 0.000 description 1
230000000702 anti-platelet effect Effects 0.000 description 1
229940124345 antianginal agent Drugs 0.000 description 1
229960004676 antithrombotic agent Drugs 0.000 description 1
125000005605 benzo group Chemical group 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
238000009835 boiling Methods 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
229940049636 dobesilic acid Drugs 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002969 morbid Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
239000000106 platelet aggregation inhibitor Substances 0.000 description 1
229940020573 plavix Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000000746 purification Methods 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
150000003460 sulfonic acids Chemical class 0.000 description 1
239000000725 suspension Substances 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000002792 vascular Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Heart & Thoracic Surgery (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20054763A 2003-04-25 2005-10-17 Krystallinsk clopidogrel og fremgangsmate for fremstilling derav NO333586B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN413MU2003		2003-04-25
PCT/IN2004/000112 WO2004106344A2 (fr)	2003-04-25	2004-04-22	Sels de clopidogrel et procede de preparation

Publications (3)

Publication Number	Publication Date
NO20054763D0 NO20054763D0 (no)	2005-10-17
NO20054763L NO20054763L (no)	2006-01-16
NO333586B1 true NO333586B1 (no)	2013-07-15

Family

ID=33485475

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20054763A NO333586B1 (no)	2003-04-25	2005-10-17	Krystallinsk clopidogrel og fremgangsmate for fremstilling derav

Country Status (13)

Country	Link
US (2)	US7732608B2 (fr)
EP (4)	EP1618111B1 (fr)
KR (1)	KR20060013376A (fr)
CY (1)	CY1116554T1 (fr)
DE (1)	DE04770646T1 (fr)
DK (1)	DK1618111T3 (fr)
ES (1)	ES2531088T3 (fr)
HR (1)	HRP20150056T1 (fr)
NO (1)	NO333586B1 (fr)
PL (1)	PL1618111T3 (fr)
PT (1)	PT1618111E (fr)
SI (1)	SI1618111T1 (fr)
WO (1)	WO2004106344A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10305984A1 (de) *	2003-02-13	2004-09-02	Helm Ag	Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen
AU2003238664A1 (en) *	2003-03-12	2004-09-30	Cadila Healthcare Limited	Polymorphs and amorphous form of (s) - (+) -clopidogrel bisulfate
EP1618111B1 (fr)	2003-04-25	2014-12-24	Cadila Healthcare Limited	Sels de clopidogrel et procede de preparation
PL1680430T3 (pl) *	2003-11-03	2010-06-30	Cadila Healthcare Ltd	Sposoby wytwarzania postaci i (s)-(+)-wodorosiarczanu klopidogrelu
US20070249660A1 (en) *	2004-02-24	2007-10-25	Weber Beat T	Pharmacologically Acceptable Salts of Clopidogrel
CN1997647A (zh) *	2004-04-20	2007-07-11	赛诺菲-安万特	氯吡格雷盐及其多晶型物
WO2006074066A1 (fr) *	2004-12-30	2006-07-13	Nektar Therapeutics	Formulation non cristalline comprenant du clopidogrel
ES2391410T3 (es)	2005-09-05	2012-11-26	Cadila Healthcare Limited	Procedimientos para la preparación de diferentes formas de (s)-(+)-clopidogrel besilato
ATE498626T1 (de) *	2006-09-25	2011-03-15	Adamed Sp Zoo	Neues clopidogrel-salz und seine kristallinen formen
KR101378596B1 (ko)	2006-12-27	2014-03-26	경동제약 주식회사	결정성 클로피도그렐 · 황산염 형태 ｉ의 제조방법
US7935697B2 (en)	2006-12-28	2011-05-03	Kinex Pharmaceuticals, Llc	Compositions for modulating a kinase cascade and methods of use thereof
KR100805675B1 (ko)	2007-03-07	2008-02-21	한림제약(주)	클로피도그렐 베실레이트를 포함하는 약학 조성물 및 그의제조방법
EP2062909A1 (fr) *	2007-11-21	2009-05-27	SOLVAY (Société Anonyme)	Production de peptides et procédé de purification
KR100920932B1 (ko) *	2007-12-05	2009-10-20	한림제약(주)	결정형의 클로피도그렐 벤젠술폰산염의 제조방법
EP2107061A1 (fr)	2008-04-02	2009-10-07	Krka Tovarna Zdravil, D.D., Novo Mesto	Procédé de préparation de clopidogrel enrichi optiquement
WO2012123958A1 (fr)	2011-02-14	2012-09-20	Cadila Healthcare Limited	Sels très purs de clopidogrel exempts d'impuretés génotoxiques
CN102199161B (zh) *	2011-03-30	2013-07-03	天津红日药业股份有限公司	一种苯磺酸氯吡格雷晶型ⅰ及其制备方法和用途
CN102285996A (zh) *	2011-03-30	2011-12-21	天津红日药业股份有限公司	一种苯磺酸氯吡格雷晶型ⅱ及其制备方法和用途
CN104193762B (zh) *	2014-08-04	2017-02-15	浙江车头制药股份有限公司	一种制备苯磺酸氯吡格雷晶型ⅲ的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2530247B1 (fr)	1982-07-13	1986-05-16	Sanofi Sa	Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
GB8608335D0 (en)	1986-04-04	1986-05-08	Pfizer Ltd	Pharmaceutically acceptable salts
FR2623810B2 (fr) *	1987-02-17	1992-01-24	Sanofi Sa	Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
FR2779726B1 (fr) *	1998-06-15	2001-05-18	Sanofi Sa	Forme polymorphe de l'hydrogenosulfate de clopidogrel
US6509348B1 (en) *	1998-11-03	2003-01-21	Bristol-Myers Squibb Company	Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
DE19857137A1 (de)	1998-12-11	2000-06-15	Bayer Ag	Integriertes Verfahren zur Herstellung von Epoxiden aus Olefinen
IN191030B (fr)	2001-01-24	2003-09-13	Cadila Healthcare Ltd
US6767913B2 (en) *	2001-12-18	2004-07-27	Teva Pharmaceutical Industries Ltd.	Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms
IL166593A0 (en)	2002-08-02	2006-01-15		Racemization and enantiomer separation of clopidogrel
WO2004074215A1 (fr) *	2003-02-03	2004-09-02	Sunil Sadanand Nadkarni	Procede de preparation de clopidogrel, ses sels et compositions pharmaceutiques
DE10305984A1 (de) *	2003-02-13	2004-09-02	Helm Ag	Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen
AU2003238664A1 (en)	2003-03-12	2004-09-30	Cadila Healthcare Limited	Polymorphs and amorphous form of (s) - (+) -clopidogrel bisulfate
EP1618111B1 (fr)	2003-04-25	2014-12-24	Cadila Healthcare Limited	Sels de clopidogrel et procede de preparation
PL1680430T3 (pl) *	2003-11-03	2010-06-30	Cadila Healthcare Ltd	Sposoby wytwarzania postaci i (s)-(+)-wodorosiarczanu klopidogrelu
EP1900358A1 (fr)	2006-09-16	2008-03-19	Cimex Pharma AG	Formulations pharmaceutiques contenant du clopidogrel

2004
- 2004-04-22 EP EP04770646.0A patent/EP1618111B1/fr not_active Expired - Lifetime
- 2004-04-22 EP EP08001523A patent/EP1927595B1/fr not_active Expired - Lifetime
- 2004-04-22 WO PCT/IN2004/000112 patent/WO2004106344A2/fr not_active Ceased
- 2004-04-22 SI SI200432209T patent/SI1618111T1/sl unknown
- 2004-04-22 EP EP14192561.0A patent/EP2865681A3/fr not_active Withdrawn
- 2004-04-22 EP EP09010218A patent/EP2113506A3/fr not_active Withdrawn
- 2004-04-22 US US10/554,367 patent/US7732608B2/en not_active Expired - Fee Related
- 2004-04-22 ES ES04770646T patent/ES2531088T3/es not_active Expired - Lifetime
- 2004-04-22 KR KR1020057020142A patent/KR20060013376A/ko not_active Ceased
- 2004-04-22 DK DK04770646.0T patent/DK1618111T3/en active
- 2004-04-22 PT PT47706460T patent/PT1618111E/pt unknown
- 2004-04-22 PL PL04770646T patent/PL1618111T3/pl unknown
- 2004-04-22 DE DE4770646T patent/DE04770646T1/de active Pending
- 2004-04-22 HR HRP20150056TT patent/HRP20150056T1/hr unknown
2005
- 2005-10-17 NO NO20054763A patent/NO333586B1/no not_active IP Right Cessation
2010
- 2010-04-14 US US12/760,523 patent/US8053579B2/en not_active Expired - Fee Related
2015
- 2015-02-17 CY CY20151100161T patent/CY1116554T1/el unknown

Also Published As

Publication number	Publication date
EP1927595B1 (fr)	2013-03-06
SI1618111T1 (sl)	2015-05-29
DK1618111T3 (en)	2015-02-16
EP2865681A3 (fr)	2015-08-19
US7732608B2 (en)	2010-06-08
EP2113506A3 (fr)	2010-02-24
KR20060013376A (ko)	2006-02-09
DE04770646T1 (de)	2011-12-08
PT1618111E (pt)	2015-02-05
HRP20150056T1 (hr)	2015-04-24
US20060264636A1 (en)	2006-11-23
WO2004106344A2 (fr)	2004-12-09
US20100197923A1 (en)	2010-08-05
NO20054763L (no)	2006-01-16
EP1618111A2 (fr)	2006-01-25
EP1927595A3 (fr)	2008-09-24
ES2531088T3 (es)	2015-03-10
US8053579B2 (en)	2011-11-08
CY1116554T1 (el)	2017-03-15
EP1618111B1 (fr)	2014-12-24
WO2004106344A3 (fr)	2005-03-24
EP1927595A2 (fr)	2008-06-04
EP2865681A2 (fr)	2015-04-29
NO20054763D0 (no)	2005-10-17
EP2113506A2 (fr)	2009-11-04
PL1618111T3 (pl)	2015-06-30

Legal Events

Date	Code	Title	Description
2018-11-26	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US8053579B2 (en)	2011-11-08	Salts of clopidogrel and process for preparation
AU2010308028A1 (en)	2012-04-19	Pyrrolo[2,3-d] pyrimidine compounds
SK283589B6 (sk)	2003-10-07	Tieno[2,3-d]pyrimidíndióny, spôsoby ich prípravy, farmaceutické kompozície s ich obsahom a ich použitie
JP2005522441A (ja)	2005-07-28	クロピドグレル塩酸塩の多形体及び抗トロンビン化合物としての使用
US9120801B2 (en)	2015-09-01	Tricyclic indazole compound, method of preparation and pharmaceutical composition containing it
CA3251124A1 (fr)	2023-08-17	Dérivés de 4',5'-dihydrospiro[pipéridine-4,7'-thiéno[2,3-c]pyran] utilisés en tant qu'inhibiteurs de apol1 et leurs procédés d'utilisation
EP0769007A1 (fr)	1997-04-23	Derives de 2-ureido-benzamide
US9174953B2 (en)	2015-11-03	Bicyclic thiazoles as allosteric modulators of mGluR5 receptors
EP1057814B1 (fr)	2005-03-09	Derives de tetrahydrobenzindole
NO146359B (no)	1982-06-07	Analogifremgangsmaate ved fremstilling av terapeutisk aktive cyproheptadinderivater
CA2512280A1 (fr)	2004-09-16	Derive benzofurane
CZ217495A3 (en)	1996-03-13	2,3-cyclically condensed 1,4-dihydropyridines, process of their preparation, medicaments in which said substances are comprised and their use
HUT64759A (en)	1994-02-28	Method for producing tetrazolyl-(phenoxy-and phenoxy-alkyl-)-pyridinyl-pyridazines
JPH0586067A (ja)	1993-04-06	光学活性なチエノトリアゾロジアゼピン化合物
WO2007039578A1 (fr)	2007-04-12	Composes d'azabenzophenone substitues par imidazolyle
WO2007039580A1 (fr)	2007-04-12	Composes de benzophenone substitues par imidazolyle
JP2022081702A (ja)	2022-06-01	ピラゾール化合物
GB2363377A (en)	2001-12-19	Novel thieno[2,3-d]pyrimidinediones
HU195810B (en)	1988-07-28	Process for preparing new 8alpha-acyl-amino-ergoline derivatives and pharmaceutical compositions containing such compounds
US20100081824A1 (en)	2010-04-01	Processes For the preparation of different forms of (S)-(+)-Clopidogrel besylate
WO2009080469A1 (fr)	2009-07-02	Procédé de préparation de bisulfate de clopidogrel de forme i
JPH05117280A (ja)	1993-05-14	アミノ酸置換チアゼトキノリン−３−カルボン酸誘導体
WO2007039581A1 (fr)	2007-04-12	Composes de diazabenzophenone substitues par imidazolyle
JP2007516166A (ja)	2007-06-21	血小板凝集阻害剤の無晶形の製法